ReNEW: A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.

Start Date30 May 2024

Sponsor / Collaborator

Stealth BioTherapeutics, Inc.

EUCTR2021-003907-16-NL / Unknown statusPhase 3

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondrial Disease Resulting from Pathogenic Nuclear DNA Mutations (nPMD)

Start Date21 Jul 2022

Sponsor / Collaborator

Stealth BioTherapeutics, Inc.

NCT05162768 / Active, not recruitingPhase 3

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower

SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD).

Start Date29 Apr 2022

Sponsor / Collaborator

Stealth BioTherapeutics, Inc.

100 Clinical Results associated with Elamipretide Hydrochloride

100 Translational Medicine associated with Elamipretide Hydrochloride

100 Patents (Medical) associated with Elamipretide Hydrochloride

317

Literatures (Medical) associated with Elamipretide Hydrochloride

01 Dec 2024·Cellular and molecular life sciences : CMLS

Mitochondrial oxidative damage reprograms lipid metabolism of renal tubular epithelial cells in the diabetic kidney

Article

Author: Zhu, Guozhen ; Li, Jing ; Niu, Hiumin ; Wang, Lihua ; Wu, Wenjie ; Shi, Honghong ; Wan, Xing ; Ren, Xiayu ; Chen, Yiliang ; Li, Yafeng ; Tan, Enxue ; Hou, Yanjuan

Abstract:

The functional and structural changes in the proximal tubule play an important role in the occurrence and development of diabetic kidney disease (DKD). Diabetes-induced metabolic changes, including lipid metabolism reprogramming, are reported to lead to changes in the state of tubular epithelial cells (TECs), and among all the disturbances in metabolism, mitochondria serve as central regulators. Mitochondrial dysfunction, accompanied by increased production of mitochondrial reactive oxygen species (mtROS), is considered one of the primary factors causing diabetic tubular injury. Most studies have discussed how altered metabolic flux drives mitochondrial oxidative stress during DKD. In the present study, we focused on targeting mitochondrial damage as an upstream factor in metabolic abnormalities under diabetic conditions in TECs. Using SS31, a tetrapeptide that protects the mitochondrial cristae structure, we demonstrated that mitochondrial oxidative damage contributes to TEC injury and lipid peroxidation caused by lipid accumulation. Mitochondria protected using SS31 significantly reversed the decreased expression of key enzymes and regulators of fatty acid oxidation (FAO), but had no obvious effect on major glucose metabolic rate-limiting enzymes. Mitochondrial oxidative stress facilitated renal Sphingosine-1-phosphate (S1P) deposition and SS31 limited the elevated Acer1, S1pr1 and SPHK1 activity, and the decreased Spns2 expression. These data suggest a role of mitochondrial oxidative damage in unbalanced lipid metabolism, including lipid droplet (LD) formulation, lipid peroxidation, and impaired FAO and sphingolipid homeostasis in DKD. An in vitro study demonstrated that high glucose drove elevated expression of cytosolic phospholipase A2 (cPLA2), which, in turn, was responsible for the altered lipid metabolism, including LD generation and S1P accumulation, in HK-2 cells. A mitochondria-targeted antioxidant inhibited the activation of cPLA2f isoforms. Taken together, these findings identify mechanistic links between mitochondrial oxidative metabolism and reprogrammed lipid metabolism in diabetic TECs, and provide further evidence for the nephroprotective effects of SS31 via influencing metabolic pathways.

01 Mar 2024·Mitochondrion

Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction

Review

Author: Liu, Weixin ; Luo, Yunchang ; Li, Ninjing ; Zhang, Guohui ; He, Libing ; Zeng, Qin ; Han, Changli ; Zhao, Yuhong ; Du, Xinrong

Due to the pivotal role of mitochondria in the generation of adenosine triphosphate (ATP) and the regulation of cellular homeostasis, mitochondrial dysfunction may exert a profound impact on various physiological systems, potentially precipitating a spectrum of distinct diseases. Consequently, research pertaining to mitochondrial therapeutics has assumed increasing significance, warranting heightened scrutiny. In recent years, the field of mitochondrial therapy has witnessed noteworthy advancements, with active exploration into diverse pharmacological agents aimed at ameliorating mitochondrial function. Elamipretide (SS-31), a novel synthetic mitochondrial-targeted antioxidant, has emerged as a promising candidate with extensive therapeutic potential. Its notable attributes encompass the mitigation of oxidative stress, the suppression of inflammatory processes, the maintenance of mitochondrial dynamics, and the prevention of cellular apoptosis. As such, SS-31 may emerge as a viable choice for the treatment of mitochondrial dysfunction-related ailments in the foreseeable future. This article extensively expounds upon the superiority of SS-31 over natural antioxidants and traditional mitochondrial-targeted antioxidants, delves into its mechanisms of modulating mitochondrial function, and comprehensively summarizes its applications in alleviating mitochondrial dysfunction-associated disorders. Furthermore, we offer a comprehensive outlook on the expansive prospects of SS-31's future development and application.

01 Jan 2024·Acta biomaterialia

Platelet membrane-coated bio-nanoparticles of indocyanine green/elamipretide for NIR diagnosis and antioxidant therapy in acute kidney injury

Article

Author: Hu, Xiaojuan ; Fan, Weijiao ; Chen, Yang ; Yao, Shijie ; Yang, Xianghong ; Wu, Danping ; Mou, Xiaozhou ; Cai, Yu

Acute kidney injury (AKI) is a prevalent condition in critically ill patients that is often associated with significant morbidity and mortality. As the lack of effective early diagnosis methods often delays AKI treatment, there is currently no definitive clinical intervention available. In this study, we aimed to address these challenges by developing a nano-system called Platelet membranes-ICG-SS31-PLGA (PISP), which was designed to selectively target to the kidney site, taking advantage of the natural tendency of platelets to accumulate at sites of vascular injury. This approach allowed for the accumulation of PISP within the kidney as the disease progresses. By incorporating ICG, the in vivo distribution of PISP can be observed for NIR diagnosis of AKI. This non-invasive imaging technique holds great promise for early detection and monitoring of AKI. Furthermore, Elamipretide (SS31) acts as a mitochondria-targeted antioxidant that protects against mitochondrial damage and reduces oxidative stress, inflammation, and apoptosis. The combination of diagnostic and therapeutic capabilities within a single nano-system makes the PISP approach a valuable tool for addressing AKI. This intervention helps to prevent the deterioration of AKI and promotes the recovery. STATEMENT OF SIGNIFICANCE.

News (Medical) associated with Elamipretide Hydrochloride

18 Sep 2024

·www.prnewswire.com

Stealth BioTherapeutics Presents New Bevemipretide (SBT-272) Data at Keystone Symposium Targeting Dry Age-Related Macular Degeneration

NEEDHAM, Mass., Sept. 18, 2024 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the presentation of new bevemipretide (SBT-272) preclinical data demonstrating topical ocular delivery to the retina with protective effects observed in models of AMD. The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and Emerging Therapies held September 17-19, 2024, in Pacific Grove, CA. In this study, the distribution profile of ocular topical bevemipretide and its protective effects in models of AMD were evaluated. In animal models, bevemipretide eyedrops were well-tolerated and demonstrated desirable ocular posterior segment and systemic exposure profiles with optimized delivery to the retina and low plasma concentrations. In a rat model of bright light-induced retinal degeneration, topical administration of bevemipretide significantly attenuated the loss of retinal thickness. Protective effects of bevemipretide were also investigated using iPSC-derived retinal pigment epithelial (RPE) cells from patients with AMD. Treatment with bevemipretide significantly improved viability of patient-derived RPE cells and reduced cellular and mitochondrial ROS production in ARPE-19 cells treated with hydroquinone, a model used to mimic cigarette smoke-induced oxidative stress in AMD. "In dry AMD, mitochondrial dysfunction ultimately leads to the degeneration and loss of photoreceptors and reduction in the EZ to RPE thickness within the macula, resulting in progressive loss of visual function," said Reenie McCarthy, CEO of Stealth BioTherapeutics. "We demonstrated in our ReCLAIM-2 study of elamipretide, our lead investigational compound, that our mitochondrial-targeted approach may reduce the progressive photoreceptor loss associated with declining visual function. We designed bevemipretide as a next-generation approach to offer a broader range of potential therapeutic options to patients living with this devastating disease. We plan to initiate clinical studies to support further development of topical bevemipretide as a potentially disease-modifying therapy in dry AMD." About Dry AMD AMD is a leading cause of irreversible blindness estimated by the Vision and Eye Health Surveillance System to affect 19.8 million Americans aged 40 and older (Rein 2022). Dry AMD, which accounts for 85% to 90% of these cases (Schultz 2021), is a progressive retinal disease in which the mitochondrial-rich photoreceptors (specialized neurons that convert light into electrical signals required for normal visual function) in the retina suffer progressive damage and death, leading to loss of vision. Mitochondrial dysfunction is known to precede clinical symptoms of AMD and increase commensurate with AMD disease progression (Feher 2006; Karunadharma 2010; Terluk 2015). Photoreceptor loss can be quantified using optical coherence tomography (OCT), a noninvasive imaging technique, to measure thickness between the ellipsoid zone (EZ), a mitochondrial-dense layer of the photoreceptors, and the RPE (i.e., EZ-RPE thickness). Loss of photoreceptors has been shown to precede and predict the loss of visual function and areas of geographic atrophy in dry AMD. About Stealth BioTherapeutics Stealth BioTherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for age-related and rare genetic diseases involving mitochondrial dysfunction. The Company is studying elamipretide, its lead investigational product candidate, in a Phase 3 development effort in dry AMD. Elamipretide is also under evaluation for primary mitochondrial myopathy, a rare skeletal myopathic disease, with pivotal Phase 3 data expected by year-end, and is under review by the Food and Drug Administration for Barth syndrome, an ultra-rare cardioskeletal disease, with a Prescription Drug User Fee Act date in January 2025. The Company is developing its second-generation clinical-stage candidate, bevemipretide (SBT-272), for ophthalmic and neurological disease indications. The Company has a deep pipeline of novel mitochondria-targeted compounds under evaluation as therapeutic product candidates. Media Contact Anna Stallmann Anna Stallmann Communications [email protected] Investor Contact Austin Murtagh Precision AQ [email protected] SOURCE Stealth BioTherapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3

12 Sep 2024

·www.prnewswire.com

Stealth BioTherapeutics Announces Participation at Upcoming Ophthalmology Conferences

NEEDHAM, Mass., Sept. 12, 2024 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced its participation at key upcoming ophthalmology conferences to discuss the Company's clinical development efforts in dry age-related macular degeneration (dry AMD), including new analyses of the Phase 2 ReCLAIM-2 study of elamipretide and data that support the primary endpoint design of the Phase 3 ReNEW and ReGAIN studies of elamipretide. At the 24th Euretina Congress, being held Sept. 19-22 in Barcelona, the Company will present a late-breaking e-poster titled: "Impact of Baseline Quantitative Ellipsoid Zone Integrity Parameters on Photoreceptor Loss in Dry AMD: A Post-Hoc Analysis of ReCLAIM-2". At the American Academy of Ophthalmology (AAO) Meeting, which is being held Oct. 18-21 in Chicago, the Company will present a poster: "ReNEW and ReGAIN - Phase 3 Dry AMD Trials with Elamipretide (ELAM): Modeling the Primary Endpoint of Photoreceptor Loss" Earlier this year, Stealth began enrolling participants in the global Phase 3 ReNEW study (NCT06373731) as part of its Phase 3 clinical program for elamipretide in patients with dry AMD. The program consists of the two Phase 3 trials, ReNEW and ReGAIN. Both trials will evaluate the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide in participants with dry AMD. The primary efficacy endpoint will measure the rate of change in the macular area of photoreceptor loss, assessed by spectral domain-optical coherence tomography (SD-OCT) and ellipsoid zone (EZ) mapping at week 48. About Dry AMD AMD is the leading cause of irreversible blindness and is estimated by the Vision and Eye Health Surveillance System to affect 19.8 million Americans aged 40 and older (Rein 2022), with 85% to 90% of cases being dry AMD (Schultz 2021). Dry AMD is a progressive retinal disease in which the photoreceptors, which are specialized neurons found in the retina that convert light into electrical signals required for normal visual function, suffer progressive damage and death, leading to loss of vision. Mitochondrial dysfunction, which has been associated with aging, smoking, obesity, and cardiovascular health, is known to precede clinical symptoms of AMD and increase commensurate with AMD disease progression (Feher 2006; Karunadharma 2010; Terluk 2015). Photoreceptor loss can be quantified by measuring the thickness between the EZ and retinal pigment epithelium (i.e., EZ-RPE thickness). Loss of photoreceptors cells, or EZ attenuation, has been shown to precede and predict the loss of visual function and areas of geographic atrophy in dry AMD. About Stealth BioTherapeutics Our mission is to develop novel therapies to improve the lives of patients living with diseases of mitochondrial dysfunction. Our lead product candidate, elamipretide, is under review for Barth syndrome and in late-stage development for primary mitochondrial myopathy and dry age-related macular degeneration. We are also evaluating a topical ophthalmic formulation of our second-generation clinical-stage candidate, bevemipretide (SBT-272), for dry age-related macular degeneration, and have a deep pipeline of novel compounds under evaluation for rare neurological and myopathic diseases. Media Contact Anna Stallmann Anna Stallmann Communications [email protected] Investor Contact Austin Murtagh Precision AQ [email protected] SOURCE Stealth BioTherapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Phase 2

09 Sep 2024

·www.prnewswire.com

Stealth BioTherapeutics Announces FDA Advisory Committee Meeting to Review Elamipretide for Barth Syndrome Treatment

Meeting Scheduled with Cardiovascular and Renal Drugs Advisory Committee on October 10, 2024 NEEDHAM, Mass., Sept. 9, 2024 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that the U.S. Food and Drug Administration (FDA) will hold an advisory committee meeting with the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) on October 10, 2024 to evaluate the New Drug Application (NDA) for elamipretide, the first potential therapy for Barth syndrome. This ultra-rare, progressive disease affects approximately 150 individuals in the United States, causing severe cardiac and skeletal muscle manifestations that significantly reduce life expectancy. The NDA has been granted priority review, with a Prescription Drug User Fee Act (PDUFA) action date of January 29, 2025. "We are grateful to the patients, families, and physicians who participated in the studies that supported this new drug application, as well as to the patient and medical community members who requested a review of elamipretide as the first potential therapy for Barth syndrome," said Reenie McCarthy, Chief Executive Officer. "We look forward to meeting with the Cardiovascular and Renal Drugs Advisory Committee to discuss elamipretide's potential to improve the lives of individuals living with Barth syndrome, a devastating disease with a significant and urgent unmet medical need." If approved, this would be the first marketing authorization for elamipretide, a first-in-class mitochondria-targeted therapeutic. In addition to Barth syndrome, elamipretide is in Phase 3 trials for primary mitochondrial myopathy, with pivotal data expected by the end of 2024, and for dry age-related macular degeneration. About Barth Syndrome Barth syndrome is an ultra-rare genetic condition characterized by cardiac abnormalities leading to exercise intolerance, muscle weakness, debilitating fatigue, heart failure, recurrent infections, and delayed growth. The disease is associated with reduced life expectancy, with 85% of early deaths occurring by age 5. Barth syndrome occurs primarily in males and is estimated to affect one in 1,000,000 males worldwide or around 150 individuals in the United States. There are currently no FDA- or EMA-approved therapies for patients with Barth syndrome. Elamipretide has Orphan Drug, Fast Track and Rare Pediatric Designation from the FDA and Orphan Drug Designation from the EMA for the treatment of Barth syndrome. About Stealth BioTherapeutics Our mission is to develop novel therapies to improve the lives of patients living with diseases of mitochondrial dysfunction. Our lead product candidate, elamipretide, is under review for Barth syndrome and in late-stage development for primary mitochondrial myopathy and dry age-related macular degeneration. We are also evaluating a topical ophthalmic formulation of our second-generation clinical-stage candidate, bevemipretide (SBT-272), for dry age-related macular degeneration, and have a deep pipeline of novel compounds under evaluation for rare neurological and cardiac disease indications. Media Contact Anna Stallmann Communications Anna Stallmann [email protected] Investor Contact Austin Murtagh Precision AQ [email protected] SOURCE Stealth BioTherapeutics Inc.

Phase 3NDAPriority ReviewFast TrackOrphan Drug

100 Deals associated with Elamipretide Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D10925	-	-	DB11981

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Barth Syndrome	NDA/BLA	US	Stealth BioTherapeutics, Inc.	08 Apr 2024
dry age-related macular degeneration	Phase 3	US	Stealth BioTherapeutics, Inc.	30 May 2024
dry age-related macular degeneration	Phase 3	NZ	Stealth BioTherapeutics, Inc.	30 May 2024
Mitochondrial Complex I Deficiency	Phase 3	US	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	AU	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	DE	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	HU	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	IT	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	NL	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	NZ	Stealth BioTherapeutics, Inc.	29 Apr 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03891875 (RECLAIM-2, CTgov)	Phase 2	Age Related Macular Degeneration \| Geographic Atrophy \| Glycogen Storage Disease Type II	176	Subcutaneous elamipretide through the elamipretide delivery system (Elamipretide)	aazdmmhvct(acnbnrlkzb) = zocvvoynze guwcuftgcc (vfcrphmuzy, uzalwbunpl - rmgmzrrgsr) View more	-	17 Oct 2023
				Subcutaneos placebo through the elamipretide delivery system (Placebo)	aazdmmhvct(acnbnrlkzb) = fnkzbkgzkk guwcuftgcc (vfcrphmuzy, zqfdydxxuh - fdtrhzuixx) View more
NCT03323749 (MMPOWER-3, Pubmed)	Phase 3	Mitochondrial Myopathies	218	Elamipretide 40mg/day	mkejehjzmk(rwyuwjaxlk) = wbandxjgqn abmzvnqaqx (ckhlhhjmkl )	Negative	02 Jun 2023
ARVO2023	Phase 2	Geographic Atrophy	117	Elamipretide 40 mg once daily	wxrybvzdqh(scguzsrwfu) = twuhdsekcl zkyxnjzuxd (rfvdoitnxn ) View more	-	23 Apr 2023
				Placebo	wxrybvzdqh(scguzsrwfu) = afedewwcmf zkyxnjzuxd (rfvdoitnxn ) View more
NCT03891875 (RECLAIM-2, PRNewswire) Manual	Phase 2	Geographic Atrophy	176	ELAMIPRETIDE	nwzivgyvdb(tolnfsxstj) = aecniwmnmn exoqnkjmra (gbworkdysb )	Positive	02 May 2022
				Placebo	-
ReCLAIM-1 (AAO2021)	Phase 1	Geographic Atrophy	-	Elamipretide 40mg	kupcovdyex(houugrpzpk) = qfrvwxchsf iwtukkekub (wdymciczyb ) View more	-	13 Nov 2021
NCT03098797 (Pubmed \| Genet Med) Manual	Phase 2/3	Barth Syndrome	12	elamipretide	zuihmimmuy(audribrnjl) = iqilxhtmjr xjrlfegfxm (zafbdznbuy ) View more	Positive	01 Mar 2021
NCT01755858 (EVOLVE, CTgov)	Phase 1/2	Hypertension, Renovascular \| Renal Artery Obstruction \| Reperfusion Injury	16	Bendavia (Bendavia)	hhckvoocoo(uafhtltnxv) = sjchndyfhc mzxnowazwv (ozylhxaeon, bsheewsldk - ndthywszwc) View more	-	11 Aug 2020
				Placebo (Placebo)	hhckvoocoo(uafhtltnxv) = lggbswdloj mzxnowazwv (ozylhxaeon, ucamgvxwkt - phtrbgaory) View more
NCT02805790 (Pubmed) Manual	Phase 2	Mitochondrial Myopathies	30	elamipretide	iporncosds(pwqowhfpor) = begfkkdsgk bdhiklszso (jpmdebvxjv, 134.16)	Positive	01 Aug 2020
				Placebo	iporncosds(pwqowhfpor) = ffwlvqijbd bdhiklszso (jpmdebvxjv, 125.10)
NCT02245620 (MOTION, CTgov)	Phase 2	Muscular Diseases	41	Placebo (Placebo)	norotjnlkm(eslioyxrmq) = nuqlkgrkpw pvzdsundcu (logftzyazv, jxdczrwutk - pnqulyjikn) View more	-	23 Jun 2020
				Elamipretide (Elamipretide)	urputfosap(gfawfkncrg) = jxvhhysvff jivcutnuhz (mezpkbgrya, wholvajfnr - trdthmgbtr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis